Finanzen von Viridian Therapeutics Inc (VRDN)VRDNViridian Therapeutics Inc

Evaluating the bottom line, Viridian Therapeutics, Inc. maintains a gross margin of 100.00%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -44460.56%, while the net margin is -44760.21%. These profitability ratios, combined with a Return on Equity (ROE) of -86.93%, provide a clear picture of how effectively VRDN converts its operational activities into shareholder value.

In the context of the broader market, VRDN competes directly with industry leaders such as SUPN and HRMY. With a market capitalization of $2.54B, it holds a leading position in the sector. When comparing efficiency, VRDN's gross margin of 100.00% stands against SUPN's 73.07% and HRMY's 75.81%. Such benchmarking helps identify whether Viridian Therapeutics, Inc. is trading at a premium or discount relative to its financial performance.

The company has shown a gross margin of 100% consistently, but it has faced significant net losses, with a net income of -127,119,000 USD in Q2 2026. The forward P/E ratio is 1.0072, indicating potential undervaluation based on future earnings expectations.